1. Report Introduction 2 2. Cutaneous T- Cell Lymphoma Market Overview at a Glance 16 2.1. Total Market Share Distribution of Cutaneous T- Cell Lymphoma for 7 MM in 2017 16 2.2. Total Market Share Distribution of Cutaneous T- Cell Lymphoma for 7 MM in 2027 16 3. Cutaneous T- Cell Lymphoma Overview 17 3.1. Introduction 17 3.2. Types 17 3.3. Causes 18 3.4. Pathophysiology 19 3.5. Symptoms 19 3.6. Diagnosis 20 4. Epidemiology of Cutaneous T-Cell Lymphoma 22 4.1. United States 22 4.1.1. Assumptions and Rationale 22 4.1.2. Incident Population of Cutaneous T-Cell Lymphoma 22 4.1.3. Treatable Cases of Cutaneous T-Cell Lymphoma in the United States 24 4.1.4. Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in the United States 25 4.1.5. Gender Specific Incidence of Cutaneous T-Cell Lymphoma in the United States 26 4.1.6. Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in the United States 27 4.1.7. Early Stage Specific Incidence of CTCL in the United States 28 4.1.8. Late Stage Specific Incidence of CTCL in the United States 29 4.2. Europe 30 4.3. Assumptions and Rationale 30 4.3.1. Germany 31 4.3.1.1. Incident Population of Cutaneous T-Cell Lymphoma in Germany 32 4.3.1.2. Treatable Cases of Cutaneous T-Cell Lymphoma in the Germany 33 4.3.1.3. Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Germany 34 4.3.1.4. Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Germany 35 4.3.1.5. Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany 36 4.3.1.6. Early Stage Specific Incidence of CTCL in the Germany 37 4.3.1.7. Late Stage Specific Incidence of CTCL in the Germany 38 4.3.2. France 39 4.3.2.1. Incident Population of Cutaneous T-Cell Lymphoma in France 40 4.3.2.2. Treatable Cases of Cutaneous T-Cell Lymphoma in the France 41 4.3.2.3. Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in France 42 4.3.2.4. Gender Specific Incidence of Cutaneous T-Cell Lymphoma in France 43 4.3.2.5. Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France 44 4.3.2.6. Early Stage Specific Incidence of CTCL in the France 45 4.3.2.7. Late Stage Specific Incidence of CTCL in the France 46 4.3.3. Italy 47 4.3.3.1. Incident Population of Cutaneous T-Cell Lymphoma in Italy 47 4.3.3.2. Treatable Cases of Cutaneous T-Cell Lymphoma in the Italy 48 4.3.3.3. Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Italy 49 4.3.3.4. Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Italy 50 4.3.3.5. Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy 51 4.3.3.6. Early Stage Specific Incidence of CTCL in the Italy 52 4.3.3.7. Late Stage Specific Incidence of CTCL in the Italy 53 4.3.4. Spain 54 4.3.4.1. Incident Population of Cutaneous T-Cell Lymphoma in Spain 55 4.3.4.2. Treatable Cases of Cutaneous T-Cell Lymphoma in the Spain 56 4.3.4.3. Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Spain 57 4.3.4.4. Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Spain 58 4.3.4.5. Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain 59 4.3.4.6. Early Stage Specific Incidence of CTCL in the Spain 60 4.3.4.7. Late Stage Specific Incidence of CTCL in the Spain 61 4.3.5. United Kingdom 62 4.3.5.1. Incident Population of Cutaneous T-Cell Lymphoma in UK 62 4.3.5.2. Treatable Cases of Cutaneous T-Cell Lymphoma in the United Kingdom 63 4.3.5.3. Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in United Kingdom 64 4.3.5.4. Gender Specific Incidence of Cutaneous T-Cell Lymphoma in United Kingdom 65 4.3.5.5. Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK 66 4.3.5.6. Early Stage Specific Incidence of CTCL in the UK 66 4.3.5.7. Late Stage Specific Incidence of CTCL in the UK 67 4.4. Japan 68 4.4.1. Incident Population of Cutaneous T-Cell Lymphoma in Japan 69 4.4.2. Treatable Cases of Cutaneous T-Cell Lymphoma in the Japan 70 4.4.3. Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Japan 71 4.4.4. Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Japan 72 4.4.5. Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan 73 4.4.6. Early Stage Specific Incidence of CTCL in the Japan 74 4.4.7. Late Stage Specific Incidence of CTCL in the Japan 75 5. Treatment Algorithm 76 5.1. International Lymphoma Radiation Oncology Group Guidelines for Modern Radiation Therapy for Primary Cutaneous Lymphomas 81 5.2. United States 82 5.3. NCCN Guidelines 82 5.4. Europe 87 5.5. ESMO Guidelines 87 5.6. Joint British Association of Dermatologists and U.K. Cutaneous Lymphoma Group Guidelines 88 5.7. EORTC recommendations for the treatment of mycosis fungoides/Se´zary syndrome 89 6. Unmet Needs 91 7. Marketed Drugs 92 7.1. Istodax (Romidepsin): Celgene Corporation 93 7.1.1. Drug Description 93 7.1.2. Mechanism of Action 93 7.1.3. Advantages & Disadvantages 93 7.1.4. Safety and Efficacy 93 7.1.5. Product Profile 94 7.2. Poteligeo (Mogamulizumab): Kyowa Hakko Kirin Co, Ltd. 95 7.2.1. Drug Description 95 7.2.2. Mechanism of Action 95 7.2.3. Advantages & Disadvantages 95 7.2.4. Safety and Efficacy 96 7.2.5. Product Profile 96 7.3. Valchlor/ Ledaga (Mechlorethamine): Actelion 97 7.3.1. Drug Description 97 7.3.2. Mechanism of Action 97 7.3.3. Advantages & Disadvantages 97 7.3.4. Safety and Efficacy 98 7.3.5. Product Profile 98 7.4. Uvadex (Methoxsalen): Mallinckrodt Pharmaceuticals 99 7.4.1. Drug Description 99 7.4.2. Mechanism of Action 99 7.4.3. Advantages & Disadvantages 99 7.4.4. Safety and Efficacy 100 7.4.5. Product Profile 100 7.5. Targretin (Bexarotene): Eisai Co., Ltd. 101 7.5.1. Drug Description 101 7.5.2. Mechanism of Action 101 7.5.3. Advantages & Disadvantages 101 7.5.4. Safety and Efficacy of Targretin 102 7.5.5. Product Profile 102 7.6. Zolinza (Vorinostat): Merck Sharp & Dohme Corp. 103 7.6.1. Drug Description 103 7.6.2. Mechanism of Action 103 7.6.3. Advantages & Disadvantages 103 7.6.4. Safety and Efficacy of Zolinza 104 7.6.5. Product Profile 104 8. Emerging Drugs 105 8.1. Phase-III Drugs Analysis – Monoclonal Antibodies and Photodynamic Therapy 105 8.2. Phase-II Drugs Analysis - Histone Deacetylase (HDAC) Inhibitors 106 9. Emerging Therapies 107 9.1. Brentuximab Vedotin: Seattle Genetics 107 9.1.1. Product Description 107 9.1.2. Research and Development 108 9.1.3. Product Development Activities 110 9.1.4. Product Profile 111 9.2. SGX301: Soligenix 112 9.2.1. Product Description 112 9.2.2. Research and Development 112 9.2.3. Product Development Activities 113 9.2.4. Product Profile 113 9.3. Quisinostat: Janssen 114 9.3.1. Product Description 114 9.3.2. Research and Development 114 9.3.3. Product Development Activities 115 9.3.4. Product Profile 115 9.4. Resminostat: 4SC AG 116 9.4.1. Product Description 116 9.4.2. Research and Development 116 9.4.3. Product Development Activities 118 9.4.4. Product Profile 118 9.5. Remetinostat: Medivir AB 119 9.5.1. Product Description 119 9.5.2. Research and Development 119 9.5.3. Product Development Activities 120 9.5.4. Product Profile 120 10. Cutaneous T- Cell Lymphoma: Country-Wise Market Analysis 121 10.1. Total Market Size of Early Stage Cutaneous T- Cell Lymphoma for 7 MM in 2017-2027 121 10.2. Total Market Size of Late Stage Cutaneous T- Cell Lymphoma for 7 MM in 2017-2027 122 10.3. Total Market Size of Cutaneous T- Cell Lymphoma for 7 MM in 2017-2027 123 10.4. Assumptions and Caveats (7MM) 124 10.5. United States 126 10.5.1. Market Outlook 126 10.5.2. Stage Specific Market Size of CTCL in United States 128 10.5.3. Market Size of CTCL in United States 129 10.6. Europe 130 10.6.1. Market Outlook 130 10.6.2. Germany 132 10.6.2.1. Stage Specific Market Size of CTCL in Germany 132 10.6.2.2. Market Size of CTCL in Germany 134 10.6.3. France 135 10.6.3.1. Stage Specific Market Size of CTCL in France 135 10.6.3.2. Market Size of CTCL in France 137 10.6.4. Italy 138 10.6.4.1. Stage Specific Market Size of CTCL in Italy 138 10.6.4.2. Market Size of CTCL in Italy 140 10.6.5. Spain 141 10.6.5.1. Stage Specific Market Size of CTCL in Spain 141 10.6.5.2. Market Size of CTCL in Spain 142 10.6.6. United Kingdom 143 10.6.6.1. Stage Specific Market Size of CTCL in United Kingdom 143 10.6.6.2. Market Size of CTCL in United Kingdom 144 10.7. Japan 145 10.7.1. Market Outlook 145 10.7.2. Stage Specific Market Size of CTCL in Japan 147 10.7.3. Market Size of CTCL in Japan 148 11. Market Drivers 149 12. Market Restraints 150 13. Appendix 151 14. Report Methodology 151 14.1. Sources Used 15. DelveInsight Capabilities 153 16. Disclaimer 154 17. About DelveInsight 154

Table 1: Incident Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 22 Table 2: Treatable Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 23 Table 3: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 24 Table 4: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 25 Table 5: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 27 Table 6: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 28 Table 7: Incident Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 31 Table 8: Treatable Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 32 Table 9: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 33 Table 10: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 34 Table 11: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 36 Table 12: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 37 Table 13: Incident Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 39 Table 14: Treatable Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 40 Table 15: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 41 Table 16: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 42 Table 17: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 44 Table 18: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 45 Table 19: Incident Population of Cutaneous T-Cell Lymphoma Italy (2017-2027) 46 Table 20: Treatable Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 47 Table 21: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 48 Table 22: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 49 Table 23: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 51 Table 24: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 52 Table 25: Incident Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 54 Table 26: Treatable Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 55 Table 27: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 56 Table 28: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 57 Table 29: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 59 Table 30: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 60 Table 31: Incident Population of Cutaneous T-Cell United Kingdom (2017-2027) 61 Table 32: Treatable Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 62 Table 33: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 63 Table 34: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 64 Table 35: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 65 Table 36: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 66 Table 37: Incident Population of Cutaneous T-Cell in Japan (2017-2027) 68 Table 38: Treatable Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 69 Table 39: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 70 Table 40: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 71 Table 41: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 73 Table 42: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 74 Table 43 : Recommendations for treatment of CTCL by Radiation Therapy 80 Table 44 : Recommendations for treatment of MF stages IA, IB, and IIA 88 Table 45: List of Marketed Drugs for Cutaneous T Cell Lymphoma 91 Table 46: Market Size of Early Stage Cutaneous T-Cell Lymphoma in 7MM (USD Million) (2017-2027) 120 Table 47: Market Size of Late Stage Cutaneous T-cell Lymphoma in 7MM (USD Million) (2017-2027) 121 Table 48: Market Size of Cutaneous T-cell Lymphoma in 7MM (USD Million) (2017-2027) 122 Table 49: Forecasting parameters and assumptions for Market Forecast in 7MM (2017-2027) 123 Table 50: United States Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 127 Table 51: United States Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 128 Table 52: Germany Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 132 Table 53: Germany Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 133 Table 54: France Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 135 Table 55: France Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 136 Table 56: Italy Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 138 Table 57: Italy Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 139 Table 58: Spain Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 140 Table 59: Spain Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 141 Table 60: UK Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 142 Table 61: United Kingdom Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 143 Table 62: Japan Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 146 Table 63: Japan Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 147 Figure 1: Incident Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 22 Figure 2: Treatable Population of Cutaneous T-Cell Lymphoma in the US (2017-2027) 23 Figure 3: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 24 Figure 4: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in the US (2017-2027) 25 Figure 5: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 27 Figure 6: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in US (2017-2027) 28 Figure 7: Incident Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 31 Figure 8: Treatable Population of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 32 Figure 9: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 33 Figure 10: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 34 Figure 11: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 36 Figure 12: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2017-2027) 37 Figure 13: Incident Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 39 Figure 14: Treatable Population of Cutaneous T-Cell Lymphoma in France (2017-2027) 40 Figure 15: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 41 Figure 16: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 42 Figure 17: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 44 Figure 18: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2017-2027) 45 Figure 19: Incident Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 46 Figure 20: Treatable Population of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 47 Figure 21: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 48 Figure 22: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 49 Figure 23: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 51 Figure 24: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2017-2027) 52 Figure 25: Incident Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 54 Figure 26: Treatable Population of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 55 Figure 27: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 56 Figure 28: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 57 Figure 29: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 59 Figure 30: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2017-2027) 60 Figure 31: Incident Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 61 Figure 32: Treatable Population of Cutaneous T-Cell Lymphoma in United Kingdom (2017-2027) 62 Figure 33: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 63 Figure 34: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 64 Figure 35: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 65 Figure 36: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2017-2027) 66 Figure 37: Incident Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 68 Figure 38: Treatable Population of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 69 Figure 39: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 70 Figure 40: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 71 Figure 41: Early Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 73 Figure 42: Late Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2017-2027) 74 Figure 43:Treatment Algorithm of Cutaneous T- Cell Lymphoma 75 Figure 44:Treatment Algorithm of Cutaneous T- Cell Lymphoma 76 Figure 45:Treatment for Stage IA of Cutaneous T- Cell Lymphoma 81 Figure 46:Treatment for Stage IB-IIA of Cutaneous T- Cell Lymphoma 82 Figure 47:Treatment for Stage IIB of Cutaneous T- Cell Lymphoma 82 Figure 48:Treatment for Stage III of Cutaneous T- Cell Lymphoma 83 Figure 49:Treatment for Stage IV of Cutaneous T- Cell Lymphoma 84 Figure 50:Treatment for Primary Cutaneous CD30+ T-Cell Lymphoproliferative Disorders 84 Figure 51:Treatment for Lymphomatoid papulosis 85 Figure 52:BAD Guidelines for Mycosis Fungoides and Sezary Syndrome 87 Figure 53: United States Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 127 Figure 54: United States Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 128 Figure 55: Germany Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 132 Figure 56: Germany Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 133 Figure 57: France Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 135 Figure 58: France Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 136 Figure 59: Italy Market Size of Early & Late Stage Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 138 Figure 60: Italy Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 139 Figure 61: Spain Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 140 Figure 62: Spain Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 141 Figure 63: United Kingdom Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 142 Figure 64: United Kingdom Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 143 Figure 65: Japan Market Size of Stage Specific Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 146 Figure 66: Japan Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2017-2027) 147